{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:42:19Z","timestamp":1768016539427,"version":"3.49.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaip.2021.06.019","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T12:39:04Z","timestamp":1624624744000},"page":"3575-3583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19"],"prefix":"10.1016","volume":"9","author":[{"given":"Rohan","family":"Ameratunga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Longhurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Lehnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Euphemia","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna E.S.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"See-Tarn","family":"Woon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.06.019_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A\u00a0pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2021.06.019_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/01652176.2020.1766725","article-title":"COVID-19: animals, veterinary and zoonotic links","volume":"40","author":"Tiwari","year":"2020","journal-title":"Vet Q"},{"key":"10.1016\/j.jaip.2021.06.019_bib3","doi-asserted-by":"crossref","first-page":"e2000240","DOI":"10.1002\/bies.202000240","article-title":"The genetic structure of SARS-CoV-2 does not rule out a laboratory origin: SARS-COV-2 chimeric structure and furin cleavage site might be the result of genetic manipulation","volume":"43","author":"Segreto","year":"2021","journal-title":"Bioessays"},{"key":"10.1016\/j.jaip.2021.06.019_bib4","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2021.06.019_bib5","first-page":"00044","article-title":"Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","volume":"27","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jaip.2021.06.019_bib6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.abh1139","article-title":"Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants","volume":"373","author":"Yuan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jaip.2021.06.019_bib7","doi-asserted-by":"crossref","first-page":"e61312","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.jaip.2021.06.019_bib8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.06.019_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2021.06.019_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2021.06.019_bib12","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy","volume":"323","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2021.06.019_bib13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/CCM.0000000000004447","article-title":"Extracorporeal membrane oxygenation for coronavirus disease 2019-induced acute respiratory distress syndrome: a multicenter descriptive study","volume":"48","author":"Yang","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jaip.2021.06.019_bib14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.06.019_bib15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(20)30633-4","article-title":"Clinical course and mortality risk of severe COVID-19","volume":"395","author":"Weiss","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.06.019_bib16","first-page":"e93","article-title":"Impacts of immunosuppression and immunodeficiency on COVID-19: a systematic review and meta-analysis","volume":"81","author":"Gao","year":"2020","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.jaip.2021.06.019_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-2600(20)30228-9","article-title":"Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities","volume":"8","author":"Kirby","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2021.06.019_bib18","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s40615-020-00833-4","article-title":"Racial, economic, and health inequality and COVID-19 infection in the United States","volume":"8","author":"Abedi","year":"2021","journal-title":"J\u00a0Racial Ethn Health Disparities"},{"key":"10.1016\/j.jaip.2021.06.019_bib19","first-page":"e8399","article-title":"Protective adaptive immunity against severe acute respiratory syndrome coronaviruses 2 (SARS-CoV-2) and implications for vaccines","volume":"12","author":"Manners","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2021.06.019_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","article-title":"Immune determinants of COVID-19 disease presentation and severity","volume":"27","author":"Brodin","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2021.06.019_bib21","first-page":"e7943","article-title":"A\u00a0comprehensive review of severe acute respiratory syndrome coronavirus 2","volume":"12","author":"Baek","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.jaip.2021.06.019_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2135","article-title":"Innate immune evasion by SARS-CoV-2: comparison with SARS-CoV","volume":"30","author":"Bouayad","year":"2020","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jaip.2021.06.019_bib23","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Auto-antibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jaip.2021.06.019_bib24","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/eji.202048959","article-title":"Complement cascade in severe forms of COVID-19: recent advances in therapy","volume":"51","author":"Chouaki Benmansour","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","article-title":"T\u00a0cell responses in patients with COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib26","doi-asserted-by":"crossref","first-page":"108699","DOI":"10.1016\/j.celrep.2021.108699","article-title":"Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD","volume":"34","author":"Zhou","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaip.2021.06.019_bib27","doi-asserted-by":"crossref","first-page":"w20249","DOI":"10.4414\/smw.2020.20249","article-title":"Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?","volume":"150","author":"Negro","year":"2020","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.jaip.2021.06.019_bib28","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.immuni.2020.11.016","article-title":"Low-avidity CD4(+) T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19","volume":"53","author":"Bacher","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2021.06.019_bib29","doi-asserted-by":"crossref","first-page":"eabd2071","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib30","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.cell.2020.10.001","article-title":"Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19","volume":"183","author":"Meckiff","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2021.06.019_bib31","doi-asserted-by":"crossref","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaip.2021.06.019_bib32","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2021.06.019_bib33","doi-asserted-by":"crossref","first-page":"916.e1","DOI":"10.1016\/j.cmi.2021.02.020","article-title":"SARS CoV-2 infections in health care workers with pre-existing T cell response: a prospective cohort study","volume":"27","author":"Casado","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaip.2021.06.019_bib34","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jaip.2021.06.019_bib35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2021.06.019_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","article-title":"Functional SARS-CoV-2-specific immune memory persists after mild COVID-19","volume":"184","author":"Rodda","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2021.06.019_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.iac.2020.03.001","article-title":"Defining common variable immunodeficiency disorders in 2020","volume":"40","author":"Ameratunga","year":"2020","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.06.019_bib38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/cei.12178","article-title":"New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin","volume":"174","author":"Ameratunga","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","article-title":"International Consensus Document (ICON): common variable immunodeficiency disorders","volume":"4","author":"Bonilla","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.019_bib40","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2019.02.004","article-title":"The European Society for Immunodeficiencies (ESID) Registry working definitions for the clinical diagnosis of inborn errors of immunity","volume":"7","author":"Seidel","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.019_bib41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2013.12.1077","article-title":"Clinical picture and treatment of 2212 patients with common variable immunodeficiency","volume":"134","author":"Gathmann","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/cei.13595","article-title":"Bronchiectasis is associated with delayed diagnosis and adverse outcomes in the New Zealand Common Variable Immunodeficiency Disorders cohort study","volume":"204","author":"Ameratunga","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib43","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3389\/fimmu.2018.02130","article-title":"Assessing disease severity in common variable immunodeficiency disorders (CVID) and CVID-like disorders","volume":"9","author":"Ameratunga","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib44","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fimmu.2016.00220","article-title":"Genetic diagnosis using whole exome sequencing in common variable immunodeficiency","volume":"7","author":"Maffucci","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib45","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12016-020-08828-z","article-title":"Perspective: application of the American College of Medical Genetics variant interpretation criteria to common variable immunodeficiency disorders","volume":"61","author":"Ameratunga","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib46","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41436-018-0012-x","article-title":"Clinical implications of systematic phenotyping and exome sequencing in patients with primary antibody deficiency","volume":"21","author":"Abolhassani","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.jaip.2021.06.019_bib47","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12016-017-8645-0","article-title":"Review: diagnosing common variable immunodeficiency disorder in the era of genome sequencing","volume":"54","author":"Ameratunga","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-3476(97)70139-2","article-title":"Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome","volume":"131","author":"Ameratunga","year":"1997","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jaip.2021.06.019_bib49","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/1744666X.2018.1481750","article-title":"Keeping it in the family: the case for considering late-onset combined immunodeficiency a subset of common variable immunodeficiency disorders","volume":"14","author":"Ameratunga","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib50","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3389\/fimmu.2019.01541","article-title":"The natural history of untreated primary hypogammaglobulinemia in adults: implications for the diagnosis and treatment of common variable immunodeficiency disorders (CVID)","volume":"10","author":"Ameratunga","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib51","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1038\/cti.2017.41","article-title":"Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus","volume":"6","author":"Ameratunga","year":"2017","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.jaip.2021.06.019_bib52","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.3389\/fimmu.2017.01965","article-title":"Clinical implications of digenic inheritance and epistasis in primary immunodeficiency disorders","volume":"8","author":"Ameratunga","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2015.07.008","article-title":"Haploinsufficiency of the NF-kappaB1 subunit p50 in common variable immunodeficiency","volume":"97","author":"Fliegauf","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaip.2021.06.019_bib54","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","article-title":"COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience","volume":"147","author":"Shields","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib55","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s10875-020-00904-5","article-title":"Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy","volume":"41","author":"London","year":"2021","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib56","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaci.2020.09.020","article-title":"Severe SARS-CoV-2 disease in the context of a NF-kappaB2 loss-of-function pathogenic variant","volume":"147","author":"Abraham","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.anai.2020.04.033","article-title":"The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019","volume":"125","author":"Fill","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib58","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10875-020-00928-x","article-title":"Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency","volume":"41","author":"Delavari","year":"2021","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib59","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib60","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaip.2020.11.006","article-title":"COVID-19 infection in 10 common variable immunodeficiency patients in New York City","volume":"9","author":"Cohen","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.019_bib61","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.anai.2020.08.017","article-title":"A\u00a0fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency","volume":"126","author":"Mullur","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib62","doi-asserted-by":"crossref","first-page":"614086","DOI":"10.3389\/fimmu.2020.614086","article-title":"Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel","volume":"11","author":"Marcus","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib63","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13223-021-00518-5","article-title":"Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma","volume":"17","author":"Ribeiro","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A\u00a0possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib65","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.jaip.2020.08.059","article-title":"Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma","volume":"8","author":"Jin","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.019_bib66","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.jaip.2020.06.046","article-title":"Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma","volume":"8","author":"Mira","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.019_bib67","doi-asserted-by":"crossref","first-page":"596761","DOI":"10.3389\/fimmu.2020.596761","article-title":"Case report: convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19","volume":"11","author":"Van Damme","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000514193","article-title":"SARS-CoV-2-associated T-cell responses in the presence of humoral immunodeficiency","volume":"182","author":"Gupta","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib69","doi-asserted-by":"crossref","first-page":"607918","DOI":"10.3389\/fimmu.2020.607918","article-title":"HCoV- and SARS-CoV-2 cross-reactive T cells in CVID patients","volume":"11","author":"Steiner","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib70","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.cmi.2020.07.029","article-title":"Personal protective equipment protecting healthcare workers in the Chinese epicentre of COVID-19","volume":"26","author":"Zhao","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaip.2021.06.019_bib71","doi-asserted-by":"crossref","first-page":"m4763","DOI":"10.1136\/bmj.m4763","article-title":"Lightening the viral load to lessen covid-19 severity","volume":"371","author":"Burgess","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2021.06.019_bib72","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/v13020304","article-title":"Relationships between viral load and the clinical course of COVID-19","volume":"13","author":"Tsukagoshi","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jaip.2021.06.019_bib73","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijid.2021.02.117","article-title":"Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital","volume":"105","author":"Mondi","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jaip.2021.06.019_bib74","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2021.06.019_bib75","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.019_bib76","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib77","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.06.019_bib78","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12249-020-01744-7","article-title":"The COVID-19 vaccine race: challenges and opportunities in vaccine formulation","volume":"21","author":"Wang","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jaip.2021.06.019_bib79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib80","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.019_bib81","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/clim.1999.4799","article-title":"Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)","volume":"93","author":"Conley","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib82","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jaip.2016.02.023","article-title":"Diagnostic criteria for common variable immunodeficiency disorders","volume":"4","author":"Ameratunga","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.019_bib83","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12016-021-08860-7","article-title":"Comparison of diagnostic criteria for common variable immunodeficiency disorders (CVID) in the New Zealand CVID study","volume":"61","author":"Ameratunga","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib84","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2666-5247(21)00069-0","article-title":"COVID-19 vaccine efficacy and effectiveness\u2014the elephant (not) in the room","volume":"2","author":"Olliaro","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jaip.2021.06.019_bib85","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.anai.2020.11.009","article-title":"Non-neutralizing antibodies and limitations of serologic testing for severe acute respiratory syndrome coronavirus 2 in patients receiving immunoglobulin replacement products","volume":"126","author":"Manian","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib86","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/1744666X.2021.1905525","article-title":"Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection","volume":"17","author":"Ameratunga","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib87","author":"Murugesan"},{"key":"10.1016\/j.jaip.2021.06.019_bib88","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2021.02.034","article-title":"Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 interferon-gamma release assay","volume":"105","author":"Echeverria","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jaip.2021.06.019_bib89","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3201\/2701.203772","article-title":"Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2\u2013specific IgG","volume":"27","author":"Schwarzkopf","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jaip.2021.06.019_bib90","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMe2035678","article-title":"(A\u00a0little) clarity on convalescent plasma for Covid-19","volume":"384","author":"Katz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.019_bib91","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jama.2021.2747","article-title":"Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis","volume":"325","author":"Janiaud","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2021.06.019_bib92","first-page":"CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review","volume":"5","author":"Valk","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2021.06.019_bib93","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.06.019_bib94","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2021.06.019_bib95","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2021.06.019_bib96","doi-asserted-by":"crossref","first-page":"100849","DOI":"10.1016\/j.eclinm.2021.100849","article-title":"Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19\u2013a double-blind randomized controlled trial","volume":"35","author":"Gunst","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaip.2021.06.019_bib97","doi-asserted-by":"crossref","first-page":"198102","DOI":"10.1016\/j.virusres.2020.198102","article-title":"Identification of high-affinity inhibitors of SARS-CoV-2 main protease: towards the development of effective COVID-19 therapy","volume":"288","author":"Mohammad","year":"2020","journal-title":"Virus Res"},{"key":"10.1016\/j.jaip.2021.06.019_bib98","first-page":"112","article-title":"Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection","volume":"133","author":"Ameratunga","year":"2020","journal-title":"N\u00a0Z Med J"},{"key":"10.1016\/j.jaip.2021.06.019_bib99","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/1744666X.2021.1912596","article-title":"Perspective: the nose and the stomach play a critical role in the NZACE2-P\u0101tari\u2217 (modified ACE2) drug treatment project of SARS-CoV-2 infection","volume":"17","author":"Ameratunga","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.019_bib100","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/vaccines9060559","article-title":"Thrombotic thrombocytopenia after COVID-19 vaccination: in search of the underlying mechanism","volume":"9","author":"Rzymski","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jaip.2021.06.019_bib101","doi-asserted-by":"crossref","first-page":"102662","DOI":"10.1016\/j.jaut.2021.102662","article-title":"Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection","volume":"121","author":"McGonagle","year":"2021","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaip.2021.06.019_bib102","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/jpc.15433","article-title":"Covid-19 and primary immunodeficiency: one-year experience","volume":"57","author":"Al Yazidi","year":"2021","journal-title":"J\u00a0Paediatr Child Health"},{"key":"10.1016\/j.jaip.2021.06.019_bib103","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/ccr3.3786","article-title":"COVID-19: Prolonged viral shedding in an HIV patient with literature review of risk factors for prolonged viral shedding and its implications for isolation strategies","volume":"9","author":"Yousaf","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jaip.2021.06.019_bib104","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/infdis\/jiab075","article-title":"Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection","volume":"223","author":"Tarhini","year":"2021","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jaip.2021.06.019_bib105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jiac.2020.12.001","article-title":"Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient","volume":"27","author":"Nakajima","year":"2021","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jaip.2021.06.019_bib106","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1093\/cid\/ciab072","article-title":"Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: a case study","volume":"73","author":"Hensley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2021.06.019_bib107","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821007029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821007029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:29:57Z","timestamp":1761974997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821007029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":107,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2213219821007029"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.06.019","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}